ArticleScientific reports2025
Nanoparticles of non-porphyrinic covalent organic frameworks as contrast agents for photoacoustic imaging.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Photoacoustic imaging (PAI) is an emerging biomedical modality offering non-invasive, high-resolution imaging with molecular contrast. Its effectiveness for molecular imaging is improved by using external contrast agents such as dyes and nanostructures, which enable targeted imaging, deeper tissue penetration, and enhanced diagnostic accuracy. However, the clinical translation of these agents has been hindered by limitations in biocompatibility, biodegradability, and functionalization versatility. In this study, two porphyrin-free nanoscale covalent organic frameworks (nCOFs), TAPB-PDA and LZU-1, were evaluated as novel exogenous contrast agents for PAI. Their photoacoustic responses were systematically measured and compared with traditional contrast agents, such as gold nanoparticles (AuNPs) and ATTO532-labelled mesoporous silica nanoparticles. Experiments at 532 nm across a range of concentrations demonstrated strong photoacoustic signals from TAPB-PDA and LZU-1, with enhanced response at higher concentrations. Besides, both nCOFs also provided detectable signals at the NIR window at the lowest concentration, indicating a broad working range. A nonlinear model of the volume-integrated photoacoustic pressure is also provided. Furthermore, in vitro cytotoxicity assays indicated excellent nCOF biocompatibility, even at higher concentrations. Photostability tests under prolonged pulsed laser irradiation revealed that both nCOFs exhibit good resistance to photobleaching and partial signal recovery under intermittent excitation. Collectively, these findings highlight the potential of TAPB-PDA and LZU-1 nCOFs as biocompatible, biodegradable, and functionally versatile contrast agents for advanced photoacoustic imaging.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.